Published in Blood Weekly, December 15th, 1997
But approximately a quarter of these new corneas are destroyed by the recipient's immune system within four years of the operation.
At the British Society for Immunology 5th Annual Congress, held December 2-5, 1997, in Brighton, United Kingdom, Andrew George of Imperial College School of Medicine, London, described attempts to prevent this rejection using human genes and man-made viruses.
Dr. George and his colleagues have shown that tumor necrosis factor (TNF) is important in the process by...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.